This articlemay have been created or edited in return for undisclosed payments, a violation of Wikipedia'sterms of use. It may require cleanup to comply with Wikipedia'scontent policies, particularlyneutral point of view.(November 2022)

Mel KrajdenOBC is a Canadian physician who is a professor of pathology and laboratory medicine at theUniversity of British Columbia inVancouver, British Columbia. He is the medical director of theBCCDC Public Health Laboratory.^[1] Krajden obtained his BSc, MD, and FRCPC (Internal Medicine) atMcGill University, followed by a fellowship in Infectious Diseases atStanford University. He is also the medical director of the Public Health Laboratory at theBritish Columbia Centre for Disease Control. His research focuses on the prevention and care of hepatitis, human papillomavirus, and human immunodeficiency virus.

During the COVID-19 pandemic, Krajden played a key leadership role in Canada's public health response. Under his direction, the BC Centre for Disease Control, Public Health Laboratory, developed an accredited COVID-19 test within 10 days of the SARS-CoV-2 genome being released.^[3] He was a leading member of the national government'sCOVID-19 Immunity Task Force. He led many COVID-19 research projects including:

• RESPOND in February 2020^[4] to sequence the SARS-COV-2 genome from Genome British Columbia, part ofGenome Canada,^[5]
• R2ESPOND, aCanadian Institutes of Health Research funded project to research to link between genomic and heath outcomes for COVID-19 infections^[6]
• EXPands, a project to address the world-wide reagent shortage at the beginning of the pandemic critical for patient testing to create reagents that could be validated in aCollege of American Pathologists accredited laboratory, and produced in scale meet the growing testing needs in British Columbia,^[7]
• a project to link transmission metadata to viral genotype and serological responses of COVID-19,^[8]
• SAfER a return-to-work study that tracked and collected data over time on infection, immunity, contacts, and clinical symptoms for 1,500 volunteer employees at BC based biotechnology companies,^[9]

Krajden was also a collaborator on many COVID-19 research projects, including: COVID-19 Germline Analysis,^[10] Immunological research on antibody and cell-mediated responses,^[11] examining the biological properties of Variants of Concern and well therapeutics work,^[12] the role ACEII plays,^[13] and, the infection rate of COVID-19 in children and youths.^[14]

Krajden serves onHealth Canada's Expert Advisory Committee on Blood Regulation and Expert Advisory Committee on Cells, Tissues, and Organs. His role on these is because of his "expertise in medical microbiology, immunology, internal medicine and infectious diseases".^[15] Krajden is also the Treasurer of theAssociation of Medical Microbiology and Infectious Disease Canada.^[16]

In addition to more than 400 publications in peer-reviewed journals,^[17] Krajden has been quoted in the lay press on subjects such as human metapneumovirus,^[18] andSARS.^[19]

Krajden was appointed as a member of theOrder of British Columbia in 2020.^[20]

This biography related to medicine in Canada is astub. You can help Wikipedia byexpanding it.

• v
• t
• e

This article about theCOVID-19 pandemic is astub. You can help Wikipedia byexpanding it.

• v
• t
• e

• Living people
• Canadian pathologists
• McGill University Faculty of Medicine alumni
• Academic staff of the University of British Columbia
• Members of the Order of British Columbia
• Canadian medical biography stubs
• COVID-19 pandemic stubs

• Webarchive template wayback links
• Articles with short description
• Short description matches Wikidata
• Wikipedia articles with undisclosed paid content from November 2022
• Year of birth missing (living people)
• All stub articles